With a short percentage of shares outstanding of 2.91%, Teva Pharmaceutical Industries Limited (NYSE:TEVA) is among the 7 Best Pet Care Stocks to Buy for Consistent Recurring Revenue.
On June 8, Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced new clinical and real-world findings supporting the effectiveness of Austedo and Austedo XR in the treatment of tardive dyskinesia
Data from the real-world IMPACT-TD study showed that patients with mild symptoms experienced measurable reductions in involuntary movement scores after three months of therapy, accompanied by improvements in their ability to perform everyday activities. The company also reported results from the three-year RIM-TD study, which demonstrated that more than half of patients responded to treatment by week 15, while an additional 23% achieved clinically meaningful improvement after that point. Management emphasized that these findings reinforce Teva’s commitment to advancing the diagnosis, treatment, and long-term management of tardive dyskinesia through evidence-based research and innovation.
Earlier, on June 4, Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced the European launch of Ahzantive, a biosimilar version of Eylea, marking another step in the expansion of its biosimilars business. The company began rolling out Ahzantive pre-filled syringes across several major European markets, including France, Germany, Spain, and the Netherlands. The launch broadens Teva’s biosimilar portfolio and enhances its position in the ophthalmology market, where healthcare systems continue to seek more affordable treatment alternatives.